CA3183559A1 - Arimoclomol for treating gaucher disease - Google Patents

Arimoclomol for treating gaucher disease

Info

Publication number
CA3183559A1
CA3183559A1 CA3183559A CA3183559A CA3183559A1 CA 3183559 A1 CA3183559 A1 CA 3183559A1 CA 3183559 A CA3183559 A CA 3183559A CA 3183559 A CA3183559 A CA 3183559A CA 3183559 A1 CA3183559 A1 CA 3183559A1
Authority
CA
Canada
Prior art keywords
active pharmaceutical
pharmaceutical ingredient
use according
day
gaucher disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3183559A
Other languages
English (en)
French (fr)
Inventor
Thomas Kirkegaard Jensen
Anders Morkeberg Hinsby
Cathrine Kolster Fog-Tonnesen
Linda INGEMANN
Christine I Dali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zevra Denmark AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3183559A1 publication Critical patent/CA3183559A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3183559A 2020-06-24 2021-06-24 Arimoclomol for treating gaucher disease Pending CA3183559A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20182067.7 2020-06-24
EP20182067 2020-06-24
PCT/EP2021/067366 WO2021260120A1 (en) 2020-06-24 2021-06-24 Arimoclomol for treating gaucher disease

Publications (1)

Publication Number Publication Date
CA3183559A1 true CA3183559A1 (en) 2021-12-30

Family

ID=71143584

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3183559A Pending CA3183559A1 (en) 2020-06-24 2021-06-24 Arimoclomol for treating gaucher disease

Country Status (14)

Country Link
US (1) US20230226036A1 (cg-RX-API-DMAC7.html)
EP (1) EP4171559B1 (cg-RX-API-DMAC7.html)
JP (3) JP2023531750A (cg-RX-API-DMAC7.html)
KR (1) KR20230035586A (cg-RX-API-DMAC7.html)
CN (1) CN116075305A (cg-RX-API-DMAC7.html)
AU (1) AU2021295437A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026396A2 (cg-RX-API-DMAC7.html)
CA (1) CA3183559A1 (cg-RX-API-DMAC7.html)
DK (1) DK4171559T3 (cg-RX-API-DMAC7.html)
ES (1) ES3056005T3 (cg-RX-API-DMAC7.html)
IL (1) IL299250A (cg-RX-API-DMAC7.html)
MX (1) MX2023000033A (cg-RX-API-DMAC7.html)
PT (1) PT4171559T (cg-RX-API-DMAC7.html)
WO (1) WO2021260120A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9662375B2 (en) * 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222994B1 (hu) 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUP9900475D0 (en) 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
JP5616336B2 (ja) * 2008-06-26 2014-10-29 オルファザイム エーピーエスＯｒｐｈａｚｙｍｅ Ａｐｓ 酵素活性の調節因子としてのＨｓｐ７０の使用
AU2010281403B2 (en) * 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
US10709700B2 (en) * 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
ES2831764T3 (es) * 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
KR102279347B1 (ko) * 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
IL299250A (en) 2023-02-01
AU2021295437A1 (en) 2023-02-02
EP4171559A1 (en) 2023-05-03
BR112022026396A2 (pt) 2023-03-14
KR20230035586A (ko) 2023-03-14
MX2023000033A (es) 2023-04-10
WO2021260120A1 (en) 2021-12-30
JP7849574B2 (ja) 2026-04-21
JP2026042936A (ja) 2026-03-11
JP2023531750A (ja) 2023-07-25
EP4171559B1 (en) 2025-09-10
ES3056005T3 (en) 2026-02-17
CN116075305A (zh) 2023-05-05
PT4171559T (pt) 2025-12-16
US20230226036A1 (en) 2023-07-20
DK4171559T3 (da) 2025-12-15
JP2026104910A (ja) 2026-06-25

Similar Documents

Publication Publication Date Title
JP6208235B2 (ja) 多発性硬化症治療のためのビオチンの使用
EP3359162B1 (en) Methods of treating injuries or conditions related to cns edema
JP7849574B2 (ja) ゴーシェ病を処置するためのアリモクロモル
US10016409B2 (en) Method for improving interstitial flow
US7713984B2 (en) Pharmaceutical uses
KR20200121819A (ko) 하지 불안 증후군을 치료하기 위한 치료제
JP4746714B2 (ja) 線維筋痛症治療用医薬組成物
HK40090895B (en) Arimoclomol for treating gaucher disease
HK40090895A (en) Arimoclomol for treating gaucher disease
US20190224208A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
TW202604498A (zh) 劑量方案
TW202416992A (zh) 雌激素受體降解劑之給藥方案
EP4695225A1 (en) Treatment for amyotrophic lateral sclerosis (als)
TWI620566B (zh) 三萜混合物用以治療多發性硬化的用途
WO2025162430A1 (zh) 一种药物联用及其在预防或治疗神经退行性疾病中的用途
JP2005538067A (ja) 副鼻腔炎の処置方法
JP2008156232A (ja) リマプロストを含有してなる頚椎症の治療および／または症状進展抑制剤
HK40083190A (en) Methods of treating lennox-gastaut syndrome using fenfluramine
HK40083824A (en) Methods of treating lennox-gastaut syndrome using fenfluramine
Eisenstat et al. Status Epilepticus in the Emergency Department, Part 2: Treatment
HK1255881A1 (zh) 使用芬氟拉明治疗lennox-gastaut综合征的方法
WO2014088106A1 (ja) 線維筋痛症の予防または治療薬

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250530

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250602

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250617

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250617

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250617

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250826

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250826

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250826

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250826

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250826

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260504